Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
Kaneko A, Kobayashi N, Miura K, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Watanabe K, Horita N, Hara Y, Kudo M, Miyazawa N, Kaneko T. Kaneko A, et al. Thorac Cancer. 2024 Apr 11. doi: 10.1111/1759-7714.15304. Online ahead of print. Thorac Cancer. 2024. PMID: 38602166 Free article.
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis.
Fukuda N, Horita N, Namkoong H, Kaneko A, Somekawa K, Tagami Y, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Fukuda N, et al. Among authors: kaneko a, kaneko t. Thorac Cancer. 2022 Jan;13(1):84-94. doi: 10.1111/1759-7714.14229. Epub 2021 Nov 17. Thorac Cancer. 2022. PMID: 34791815 Free PMC article.
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C, Kubo S, Tanaka K, Tagami Y, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Koizumi H, Miura K, Miyazawa N, Kaneko T. Matsumoto H, et al. Among authors: kaneko a, kaneko t. Thorac Cancer. 2022 Jan;13(2):228-235. doi: 10.1111/1759-7714.14252. Epub 2021 Dec 5. Thorac Cancer. 2022. PMID: 34866339 Free PMC article.
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Kubo S, Kobayashi N, Matsumoto H, Somekawa K, Kaneko A, Hashimoto H, Teranishi S, Watanabe K, Horita N, Hara Y, Kudo M, Kaneko T. Kubo S, et al. Among authors: kaneko a, kaneko t. J Cancer Res Clin Oncol. 2023 Dec;149(19):17419-17426. doi: 10.1007/s00432-023-05457-9. Epub 2023 Oct 25. J Cancer Res Clin Oncol. 2023. PMID: 37878090
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes.
Kobayashi N, Miura K, Kaneko A, Matsumoto H, Somekawa K, Hirose T, Kajita Y, Tanaka A, Teranishi S, Sairenji Y, Kawashima H, Yumoto K, Tsukahara T, Fukuda N, Nishihira R, Kudo M, Miyazawa N, Kaneko T. Kobayashi N, et al. Among authors: kaneko a, kaneko t. Cancers (Basel). 2023 Oct 31;15(21):5248. doi: 10.3390/cancers15215248. Cancers (Basel). 2023. PMID: 37958421 Free PMC article.
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis.
Fukuda N, Horita N, Katakura S, Namkoong H, Kaneko A, Somekawa K, Tagami Y, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Fukuda N, et al. Among authors: kaneko a, kaneko t. Transl Lung Cancer Res. 2021 Aug;10(8):3550-3566. doi: 10.21037/tlcr-21-419. Transl Lung Cancer Res. 2021. PMID: 34584856 Free PMC article.
Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study.
Hoshi M, Kobayashi N, Tanaka K, Somekawa K, Kaneko A, Izawa A, Seki K, Tagami Y, Aoki A, Fujii H, Watanabe K, Horita N, Hara Y, Matsumura M, Enaka M, Hagihara M, Kaneko T. Hoshi M, et al. Among authors: kaneko a, kaneko t. Thorac Cancer. 2021 Dec;12(23):3281-3285. doi: 10.1111/1759-7714.14190. Epub 2021 Oct 25. Thorac Cancer. 2021. PMID: 34698453 Free PMC article. Review.
Adverse events induced by nivolumab and ipilimumab combination regimens.
Somekawa K, Horita N, Kaneko A, Tagami Y, Fukuda N, Matsumoto H, Namkoong H, Fujiwara Y, Minegishi K, Fukumoto T, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Somekawa K, et al. Among authors: kaneko a, kaneko t. Ther Adv Med Oncol. 2022 Feb 11;14:17588359211058393. doi: 10.1177/17588359211058393. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173819 Free PMC article.
Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan.
Matsumoto H, Kobayashi N, Shinoda S, Goto A, Kaneko A, Fukuda N, Kamimaki C, Kubo S, Watanabe K, Horita N, Hara Y, Ishikawa Y, Kaneko T. Matsumoto H, et al. Among authors: kaneko a, kaneko t. Sci Rep. 2023 Mar 30;13(1):5208. doi: 10.1038/s41598-023-31856-6. Sci Rep. 2023. PMID: 36997606 Free PMC article.
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H, Somekawa K, Horita N, Ueda S, Kaneko M, Kaneko A, Fukuda N, Izawa A, Kamimaki C, Tanaka K, Murohashi K, Fuji H, Tagami Y, Aoki A, Watanabe K, Hara Y, Kobayashi N, Kaneko T. Matsumoto H, et al. Among authors: kaneko a, kaneko t, kaneko m. Ther Adv Med Oncol. 2023 Sep 13;15:17588359231198453. doi: 10.1177/17588359231198453. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37720498 Free PMC article. Review.
993 results